Defective group-II metaboropic glutamate receptors in the hippocampus of spontaneously depressed rats.
Spontaneously depressed flinders sensitive line (FSL) rats showed a reduced expression of mGlu2/3 metabotropic glutamate receptors in the hippocampus, as compared to "non-depressed" flinders resistant line (FRL) rats. No changes in mGlu2/3 receptor protein levels were found in other brain regions, including the amygdala, hypothalamus, and cerebral cortex. Biochemical analysis of receptor signalling supported the reduction of mGlu2/3 receptors in the hippocampus of FSL rats. Accordingly, the selective mGlu2/3 receptor agonist, LY379268 (1microM) reduced forskolin-stimulated cAMP formation by 56% and 32% in hippocampal slices from FRL and FSL rats, respectively. In addition, LY379268 enhanced 3,5-dihydroxyphenylglycine-stimulated inositol phospholipid hydrolysis from 65% to 215% in hippocampal slices from FRL rats, whereas it was inactive in slices from FRL rats. We also examined the behavioural response of FSL rats to systemic injection of LY379268 (0.5mg/kg, i.p., once a day for 1-21 days) by measuring the immobility time in the forced swim test, which is known to be increased in these rats. LY379268 was administered alone or combined with the classical antidepressant, chlorimipramine (10mg/kg, i.p.). LY379268 alone had no effect at any of the selected time-points, whereas chlorimipramine alone reduced the immobility time only after 21 days of treatment. In contrast, when combined with LY379268, chlorimipramine reduced the immobility time during the first 14 days of treatment. These data support the view that mGlu2/3 receptors might be involved in the pathophysiology of depressive disorders, and that pharmacological activation of these receptors may shorten the latency of antidepressant medication.
Matrisciano
F
F
Department of Physiology and Pharmacology, University of Rome "Sapienza", Piazzale Aldo Moro, 5, 00185 Rome, Italy. fmatrisciano@hotmail.com
Caruso
A
A
Orlando
R
R
Marchiafava
M
M
Bruno
V
V
Battaglia
G
G
Gruber
S H M
SH
Melchiorri
D
D
Tatarelli
R
R
Girardi
P
P
Mathè
A A
AA
Nicoletti
F
F
D000596:Amino Acids / Q000494:pharmacology; D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology / Q000627:therapeutic use; D001522:Behavior, Animal / Q000187:drug effects; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology; D002997:Clomipramine / Q000494:pharmacology / Q000627:therapeutic use; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D003863:Depression / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D004195:Disease Models, Animal; D004347:Drug Interactions; D005786:Gene Expression Regulation / Q000187:drug effects / Q000235:genetics; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism*; D066298:In Vitro Techniques; D008734:Methoxyhydroxyphenylglycol / Q000031:analogs & derivatives / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists / Q000172:deficiency* / Q000378:metabolism; D013550:Swimming
D000596:Amino Acids; D000929:Antidepressive Agents, Tricyclic; D019086:Bridged Bicyclo Compounds, Heterocyclic; C118218:LY 379268; D012333:RNA, Messenger; D018094:Receptors, Metabotropic Glutamate; C108822:metabotropic glutamate receptor 2; D005576:Colforsin; D008734:Methoxyhydroxyphenylglycol; D000242:Cyclic AMP; D002997:Clomipramine; C010117:3,4-dihydroxyphenylglycol